Cytocom, Inc.
Cytocom, Inc. (CBLI) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CBLI · as of Jun 9, 2026
Key Statistics
Explore Cytocom, Inc. Data
cbli stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 4 · Buy rate: 75.0%
Competitors & Peers
cbli competitorsCBLI
CATB
CELU
CRGX
INXB
MACKStock Performance
Full HistoryAbout Cytocom, Inc.
Cytocom, Inc. Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workf…
what is cytocom, inc. · cbli stock overview · cytocom, inc. company profile · who is cytocom, inc. ceo · cbli NASDAQ · cytocom, inc. headquarters · cytocom, inc. business segments
About Stock Overview & Key Data
Cytocom, Inc. (CBLI) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 21, 2006. As of the latest trading session, CBLI stock price is $3.17, with a market capitalization of $226.4M. The stock has returned +252.18% over the past 12 months and +0.00% year-to-date.
According to 4 Wall Street analysts, the consensus rating for Cytocom, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2020, Cytocom, Inc. reported revenue of $262942.00 and net income of -$2.4M. For detailed data — including Cytocom, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Cytocom, Inc. (CBLI) stock price is $3.17. The stock is traded on NASDAQ under the ticker symbol CBLI. The 52-week range is $3.11 – $3.50.